Company Description
BGM Group Ltd manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China.
The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions.
It offers Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications.
In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application.
Further, it provides Xiongguan organic fertilizers to improve crop yield and soil’s chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth.
The company was formerly known as Qilian International Holding Group Limited and changed its name to BGM Group Ltd in October 2024.
BGM Group Ltd was incorporated in 2019 and is based in Chengdu, the People’s Republic of China.
| Country | China |
| Founded | 2019 |
| IPO Date | Jan 12, 2021 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 298 |
| CEO | Chen Xin |
Contact Details
Address: No. 152 Hongliang East 1st Street, No. 1703, Tianfu New District Chengdu, 610200 China | |
| Phone | 86 28 6477 5180 |
| Website | bgm.ltd |
Stock Details
| Ticker Symbol | BGM |
| Exchange | NASDAQ |
| Fiscal Year | October - September |
| Reporting Currency | USD |
| CIK Code | 0001779578 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Chen Xin | Chief Executive Officer |
| Zhanchang Xin | Chairman of the Board, President, Chief Operating Officer and Chief Scientific Officer |
| Yaxuan Zhai | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 3, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Nov 29, 2024 | 6-K | Report of foreign issuer |
| Nov 29, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Nov 27, 2024 | 6-K | Report of foreign issuer |
| Nov 22, 2024 | EFFECT | Notice of Effectiveness |
| Nov 5, 2024 | F-3 | Filing |
| Oct 22, 2024 | 6-K | Report of foreign issuer |
| Oct 16, 2024 | SC 13D | General statement of acquisition of beneficial ownership |
| Oct 10, 2024 | 6-K/A | Filing |
| Sep 9, 2024 | 6-K | Report of foreign issuer |